Levosimendan Eql Pharma

Levosimendan, the active ingredient in Levosimendan Eql Pharma, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure syndromes where enhanced myocardial contractility is required.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of low‑output failure. Chronic heart failure with reduced ejection fraction: provides symptomatic relief and may improve exercise tolerance. Cardiogenic shock: offers hemodynamic support when conventional inotropes are insufficient.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may be accompanied by vomiting. - Dizziness: often related to blood pressure changes. - Hypotension: transient drop in systolic pressure. - Flushing: warm sensation, usually self‑limited. - Tachycardia: mild increase in heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Sudden cardiac death: rare but reported in high‑risk patients. - Pulmonary edema: worsening respiratory status.

Levosimendan requires careful patient assessment and monitoring before and during infusion. - Hypotension: monitor blood pressure closely; adjust infusion rate if needed. - Renal impairment: assess renal function and consider dose adjustment. - Hepatic impairment: use with caution; monitor liver enzymes. - Concomitant vasodilators: increased risk of excessive hypotension; titrate combined therapy. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect leading to severe hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): risk of profound hypotension and arrhythmias. - Other calcium sensitizers: potential for excessive inotropic stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: monitor for additive blood pressure reduction. - Diuretics: watch for electrolyte disturbances and volume depletion.